Licensing & partnership
Sino Biopharmaceutical Expands Global Partnerships
Sino Biopharmaceutical highlighted its two-way innovation partnerships at the China International Import Expo, including Sanofi's global license for the Chinese-developed JAK/ROCK inhibitor 安煦. The company and GSK are working to bring bepirovirsen, an investigational therapy targeting a functional cure for chronic hepatitis B, to Chinese patients. Sino Biopharmaceutical and Boehringer Ingelheim announced an agreement covering six preclinical cancer projects, with a stated total deal value of $7 billion.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.